Xuru Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuru Wang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Lixin Wang
Southeast University 1 Department of Microbiology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, School of Medicine Nanjing, China
17 shared publications - Ning Pan
Southeast University 1 Department of Microbiology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, School of Medicine Nanjing, China
17 shared publications - Chengdong Wu
Southeast University 1 Department of Microbiology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, School of Medicine Nanjing, China
16 shared publications - Chunguang Yan
Southeast University 1 Department of Microbiology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, School of Medicine Nanjing, China
16 shared publications - Fengjiao Zhu
Southeast University 1 Department of Microbiology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, School of Medicine Nanjing, China
16 shared publications - Jing Chen
Southeast University 1 Department of Microbiology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, School of Medicine Nanjing, China
16 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S10 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 does not exacerbate DDP-induced liver or kidney toxicity.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S10 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 does not exacerbate DDP-induced liver or kidney toxicity.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies (AB) that are poorly immunogenic or immunosuppressive, creating a major barrier to the success of coadministered or second-line immunotherapies. In this study, we found reduced circulating levels of thymosin alpha-1 (Tα-1), a key endogenous peptide hormone with immunomodulatory activity, after chemotherapy treatment in patients with multiple types of cancer and in mice bearing established tumors. Tα-1 bound to tumor ABs and interacted with AB-borne microRNAs, including miR-146a-5p, following the phagocytosis of ABs into the endolysosomal compartment of dendritic cells (DC). The interaction with Tα-1 protected miR-146a-5p from lysosomal RNase A–mediated degradation, allowing miR-146a-5p–mediated activation of Toll-like receptor 7 (TLR7) that licenses DC maturation, migration to tumor-draining lymph nodes, and presentation of tumor antigens to activate tumor-specific CD8+ T cells. Therapeutic Tα-1 supplementation produced strong synergy with chemotherapy to control established tumors in mice with high miR-146a-5p expression in a TLR7-dependent manner. These findings establish Tα-1 as a pivotal endogenous microRNA chaperone that unlocks a critical limiting step of DC licensing, empowering robust antitumor immunity after chemotherapy. Significance:Tα-1 promotes miR146a-5p-mediated TLR7 signaling in dendritic cells to enhance chemotherapy-induced immunity, offering a foundation for developing Tα-1-based approaches to elicit or amplify immune responses against diverse tumors.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies (AB) that are poorly immunogenic or immunosuppressive, creating a major barrier to the success of coadministered or second-line immunotherapies. In this study, we found reduced circulating levels of thymosin alpha-1 (Tα-1), a key endogenous peptide hormone with immunomodulatory activity, after chemotherapy treatment in patients with multiple types of cancer and in mice bearing established tumors. Tα-1 bound to tumor ABs and interacted with AB-borne microRNAs, including miR-146a-5p, following the phagocytosis of ABs into the endolysosomal compartment of dendritic cells (DC). The interaction with Tα-1 protected miR-146a-5p from lysosomal RNase A–mediated degradation, allowing miR-146a-5p–mediated activation of Toll-like receptor 7 (TLR7) that licenses DC maturation, migration to tumor-draining lymph nodes, and presentation of tumor antigens to activate tumor-specific CD8+ T cells. Therapeutic Tα-1 supplementation produced strong synergy with chemotherapy to control established tumors in mice with high miR-146a-5p expression in a TLR7-dependent manner. These findings establish Tα-1 as a pivotal endogenous microRNA chaperone that unlocks a critical limiting step of DC licensing, empowering robust antitumor immunity after chemotherapy. Significance:Tα-1 promotes miR146a-5p-mediated TLR7 signaling in dendritic cells to enhance chemotherapy-induced immunity, offering a foundation for developing Tα-1-based approaches to elicit or amplify immune responses against diverse tumors.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S12 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
CRISPR‐Cas13d system decreased miR146a-5p expression.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S12 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
CRISPR‐Cas13d system decreased miR146a-5p expression.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
AB-borne ssRNAs are required for Tα-1 to promote DC maturation.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
AB-borne ssRNAs are required for Tα-1 to promote DC maturation.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 promotes AB-pulsed DC maturation during the uptake of ABs.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 promotes AB-pulsed DC maturation during the uptake of ABs.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S13 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 facilities DCs maturation by AB-borne miR146a-5p.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S13 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 facilities DCs maturation by AB-borne miR146a-5p.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S11 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 combined with DDP enhances anti-tumor immunity in melanoma mice.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S11 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 combined with DDP enhances anti-tumor immunity in melanoma mice.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 promotes splenic cDC1 maturation during the phagocytosis of ABs.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Tα-1 promotes splenic cDC1 maturation during the phagocytosis of ABs.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S6 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Deletion of TLR7 impairs Tα-1-mediated DC maturation when phagocytosis of ABs.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S6 from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Deletion of TLR7 impairs Tα-1-mediated DC maturation when phagocytosis of ABs.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Tables from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Table S1. Candidate miRNAs and their sequencing information Table S2. RNA and miRNA quality metrics of input and IP samples Table S3. Baseline characteristics.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables from Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Table S1. Candidate miRNAs and their sequencing information Table S2. RNA and miRNA quality metrics of input and IP samples Table S3. Baseline characteristics.